End-of-day quote
Shenzhen S.E.
06:00:00 2024-07-11 pm EDT
5-day change
1st Jan Change
29.28
CNY
0.00%
+13.71%
-25.44%
PharmaBlock Sciences, Inc.'s Equity Buyback announced on October 31, 2023, has closed with 836,090 shares, representing 0.42% for CNY 30.03 million.
The company closed its plan on May 30, 2024.
PharmaBlock Sciences, Inc. Announces Dividend on Share A for the Year 2023, Payable on June 14, 2024
Jun. 07
CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.
May. 30
CI
PharmaBlock Sciences, Inc.'s Equity Buyback announced on October 31, 2023, has closed with 836,090 shares, representing 0.42% for CNY 30.03 million.
May. 29
CI
PharmaBlock Sciences, Inc. Approves Cash Dividend for the Year 2023
May. 20
CI
PharmaBlock Proposes Final Dividend for 2023
Apr. 23
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 22
CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.
Apr. 01
CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.
Apr. 01
CI
Tranche Update on PharmaBlock Sciences, Inc.'s Equity Buyback Plan announced on October 31, 2023.
Jan. 02
CI
PharmaBlock Sciences, Inc Opens HPAPI GMP Facility at Zhejiang Manufacturing Site
Dec. 26
CI
PharmaBlock Sciences, Inc.(SZSE:300725) dropped from Shenzhen Stock Exchange Component A Share Index
Dec. 11
CI
PharmaBlock Sciences, Inc.(SZSE:300725) dropped from Shenzhen Stock Exchange Component Index
Dec. 11
CI
PharmaBlock Sciences, Inc. announces an Equity Buyback for CNY 40 million worth of its shares.
23-10-30
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
PharmaBlock Sciences, Inc. authorizes a Buyback Plan.
23-10-29
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-14
CI
Pharmablock Sciences, Inc. Announces Final Dividend on Share A for 2022, Payable in June 13, 2023
23-06-06
CI
Pharmablock Sciences, Inc. Approves Election of Jie Yuanping and Wu Juanjuan as Non-Independent Directors
23-05-15
CI
Pharmablock Sciences, Inc. Approves Final Cash Dividend for the Year 2022
23-05-15
CI
PharmaBlock Sciences, Inc. Proposes Final Cash Dividend for the Year 2022
23-04-24
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-21
CI
PharmaBlock Opens New R&D Facility in Pennsylvania
23-03-27
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-25
CI
PharmaBlock Sciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-12
CI
Pharmablock Sciences, Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 13, 2022
22-06-07
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PharmaBlock Sciences Nanjing Inc is a company mainly engaged in design, synthesis and sales of pharmaceutical molecular building blocks. The Company's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The Company is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.
More about the company
Last Close Price
29.28
CNY
Average target price
37.5
CNY
Spread / Average Target
+28.07%
Consensus
1st Jan change
Capi.
-25.44% 802M +62.17% 841B +40.42% 625B -4.31% 360B +17.62% 327B +9.79% 300B +15.66% 242B +17.90% 227B +15.14% 174B +0.66% 162B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1